AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04788693 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical rehabilitation of gait without motor imagery
Description: Physical rehabilitation of gait is a type of non-invasive treatment that seeks to change the way of performing a task or motor function (in this case, gait) through movement modification and corrected repeated practice, taking into account the alterations, limitations and considerations related to the disease suffered by the person. Motor imagery exercises are not included in this program.
Study NCT06641336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RehAtt
Description: Each patient received the RehAtt intervention.
Study NCT06589999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MP2RAGE sequence
Description: Addition of MRI sequence MP2RAGE
Study NCT05618925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N803
Description: nogapendekin alfa inbakicept (also known as ALT-803; recombinant human superagonist interleukin-15 (IL-15) complex \[also known as IL 15N72D:IL-15RαSu/IgG1 Fc complex\])
Study NCT05618925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19t-haNK suspension
Description: Derived from the parental NK-92 (aNK) cell line, CD19 t-haNK is a human, allogeneic, NK cell line that has been engineered to express a CAR targeting CD19. Similar to the haNK cell line, CD19 t haNK has also been engineered to produce endoplasmic reticulum-retained IL 2 and the high-affinity (158V) variant of the Fcγ receptor (FcγRIIIa/CD16a), and thereby has enhanced CD16-targeted ADCC capabilities. CD19 t-haNK is similar to PD L1 t-haNK, differing only in the CAR that is expressed (CD19 vs PD-L1).
Study NCT05618925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards. The chemical name for cyclophosphamide is 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate and has the molecular formula C7H15Cl2N2O2P•H2O and a molecular weight of 279.1.
Study NCT05618925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine phosphate is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-β-D-arabinofuranosyladenine (ara-A) that is relatively resistant to deamination by adenosine deaminase. The chemical name for fludarabine phosphate is 9H-Purin-6-amine, 2-fluoro-9-(5-0-phosphono β-D-arabino-furanosyl) (2-fluoro-ara-AMP). The molecular formula of fludarabine phosphate is C10H13FN5O7P and it has a molecular weight of 365.2.
Study NCT05618925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD and has a binding affinity for the CD20 antigen of approximately 8.0 nM.
Study NCT06669702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week home based exercise
Description: Patients allocated to the exercise arm will be prescribed a home-based walking exercise programme consisting of 30 minutes of walking on 5 days per week at an rating of perceived exertion in the range of 12-14 (somewhat hard). Each patient's heart rate range will be established during the baseline exercise test by recording the heart rate response at the required RPE target range. This will be provided to each patient to use in conjunction with the activity monitor they will be given to wear on their non-dominant wrist. The monitor reports heart rate and records daily steps, distance and activity duration.~Participants can break down the exercise time in a way that suits their time, i.e., they can do 3 × 10 minutes, 2 × 15 minutes, etc.
Study NCT06669702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Participants in this group will continue with their current routine care and will be given a diary of exercises that they can do, which are usually given to them as part of their health care routine by physiotherapists or consultants. The diary has information about yoga-like stretching practices.
Study NCT06459804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro Dry Needling
Description: Standard Physiotherapy:~It will include Hot pack (10 min), Stretching of levator scapulae (3 times with 30 seconds hold), Scapular stabilization exercises (10 times with 5 seconds hold).~Scapular Stabilization exercises will be comprised of four exercise programs. The participants will sit on the knees in 90° flexion position, and a Swiss ball will be propped up between the stomach and chest.
Study NCT06459804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: Dry Needling
Study NCT06392932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QDOT Micro ablation catheter
Description: QDOT Micro ablation catheter
Study NCT06392932 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ST SF ablation catheter
Description: ST SF ablation catheter
Study NCT06554171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy group
Description: In addition to conventional physiotherapy, training will be given in the Hippotherapy Simulator for 15 minutes a day, 5 days a week for 4 weeks. The hippotherapy simulator serves a wide range of purposes from recreational use that mimics the movements of a real horse or can make similar movements, to fitness, exercise, sports, education and therapy and is suitable for use by individuals with cerebral palsy.
Study NCT06554171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: In addition to conventional physiotherapy, the control group will be allowed to sit in the Hippotherapy Simulature for 15 minutes a day, 5 days a week for 4 weeks. However, the simulator will be kept in closed position to prevent oscillations.
Study NCT05650996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADL/Cast Care instruction
Description: Participants in the experimental group will watch a video instructing them on early ADL participation after DRF fracture treated in a cast and cast care. Participants in the experimental group will also receive a handout on ADL participation and cast care.
Study NCT05650996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cast Care Instruction
Description: Participants in the control group will watch a video instructing them on cast care. Participants in the control group will receive a handout on cast care.
Study NCT05650996 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cast Care Instruction
Description: Participants in the control group will watch a video instructing them on cast care. Participants in the control group will receive a handout on cast care.
Study NCT06673654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Topical Cream 1.5%
Description: The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
Study NCT06673654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPZELURA (Ruxolitinib) Cream
Description: The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
Study NCT06673654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
Study NCT06240130 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial pulpotomy
Description: after caries removal and pulp exposure pulp tissue is amputated and wound lavage done with 3% NaOCl in partial pulpotomy
Study NCT06240130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial pulpotomy
Description: after caries removal and pulp exposure pulp tissue is amputated and wound lavage done with 2% Chlorhexidine in partial pulpotomy
Study NCT05369767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAD, SHR-2004
Description: Ascending dose
Study NCT05369767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAD, SHR-2004 placebo
Description: Ascending dose
Study NCT06412224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRG001
Description: Administered by subretinal injection. Dosage form: injection.
Study NCT05890950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-757 and K-833
Description: Both administered orally
Study NCT05890950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to K-757 and K-833
Description: Both administered orally
Study NCT03866954 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EE-TP
Description: Ecoli thymidine phoshorylase encapsulated within autologous erythrocytes
Study NCT05025124 — intervention group
Intervention type: DEVICE
Intervention: Entia Liberty
Description: Home monitoring system
Study NCT05479539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation therapy
Description: Participants will watch 12-minute video-clips followed by 8 minutes of motor imagery. Video-clips observation and imagination will be focused un shoulder tasks occuring on the three planes of motion.
Study NCT05399238 — intervention group
Intervention type: DEVICE
Intervention: The objective is to measure the temperature of the lingual dorsum
Description: Subjects will make one visit to our clinic with burning mouth syndrome and control healthy . They will be asked to acclimate to room temperature for at least 20 minutes. Subjects are requested not to consume hot drinks or food for at least an hour before imaging and not to use any skin preparations.
Study NCT05633576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: steroid eye drops
Description: Self-administration of steroid eye drops three times a day for four consecutive weeks.
Study NCT05633576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administration of placebo eye drops three times a day for four consecutive weeks.
Study NCT06503055 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire targeting a convenience sample of medical field professionals including physicians with different specialties, pharmacists, medical students, nursing staff, and the general population in Gharbia governorate (about 1000 subjects).~The questionnaire will be written and digital in both Arabic and English versions. Moreover, an awareness campaign will be designed to educate the participants on appropriate antibiotic use principles.
Study NCT06151483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Agonist
Description: The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Study NCT06151483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: α-adrenergic receptor agonist
Description: The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Study NCT06625372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SMOF lipid
Description: The SMOF lipid is given to the patient as a fat component of total parenteral nutrition.
Study NCT06625372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: INTRALIPIDS
Description: The Intralipid will be given to the patient as fat component of total parenteral nutrition.
Study NCT05509127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified universal adhesive
Description: Application of the modified universal adhesive is done according to manufacturer's instructions using a micro-brush. It is actively rubbed for 20 seconds, gently air-dried for 5 seconds then light cured for 20 seconds.
Study NCT05509127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional universal adhesive
Description: Application of the conventional Single Bond Universal adhesive is done using a micro-brush followed by rubbing for 20 seconds, gentle air drying for 5 seconds then light curing for 20 seconds.
Study NCT05366751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-324
Description: SAGE-324 oral tablets
Study NCT06630156 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Revascularization of Immature Young Permenant Teeth
Description: An access cavity was prepared under rubber dam, isolation, root canal system disinfection was done without mechanical instrumentation. Subsequently, triple antibiotic paste was placed into the apical portion of the canal and filled to just below the CEJ. The access cavity was temporarily restored with glass ionomer.~4 weeks later, after reopening of the access, the antibiotic paste was gently flushed out of the canal with sterile normal saline. The root canal system was irrigated. A sterile #35 K-file will be introduced into the canal beyond the apical foramen using a push and pull motion to provoke bleeding from the periapical tissue. After bleeding control and formation of fresh blood clot, 3 mm of Bio (MTA) will be placed in Group A, 3 mm of Total Fill biocearmic root repair material will be placed in Group B after a moist cotton pellet was placed over the capping material and the access cavity will be sealed with G C
Study NCT06631534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 1ug/kg bolus administered over 10 minutes followed by a continuous infusion of 0.5ug/kg/hr
Study NCT06631534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: Saline (placebo)
Study NCT06701461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrodermal Activity signal
Description: Determining if the electrodermal activity signals, as measured by the Embrace Plus smartwatch) can be used to measure osteoarthritic patient pain levels.
Study NCT06747767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopy
Description: Arthroscopy
Study NCT06747767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open reduction
Description: Open reduction
Study NCT06750263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise with clamshell
Description: balance was assessed by the Berg's Balance Scale exercise. Participants were instructed to walk (step) from one end of the mat to the other according to the step pattern provided. When reached the end of the mat, instructed to return to their starting position by walking normally off the mat and starting the next stepping. repeat every sequence five times and then started a new pattern. Duration would be 30 min. clamshell exercises a Participants were instructed to lie on their side with the weaker limb facing upwards. Both hips were flexed at 45 degrees, knees flexed at 90 degrees, and neither the feet nor the back were in contact with the wall. While keeping both heels and the first metatarsal head together, participants were instructed to separate their knees and rotate the weaker limb upward. They were advised not to tilt the limb backwards and to maintain a neutral pelvic position 3,5 sets for 10 repetations twice a week for 12 weeks
Study NCT06750263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise
Description: Participants were instructed to lie on their side with the weaker limb facing upwards. Both hips were flexed at 45 degrees, the knees were flexed at 90 degrees, and neither the feet nor the back were in contact with the wall. While keeping both heels and the first metatarsal head together, participants were instructed to separate their knees and rotate the weaker limb upward. They were advised not to tilt the limb backwards and to maintain a neutral pelvic position 3,5 sets for 10 repetations twice a week for 12 weeks
Study NCT06750263 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exercise
Description: Participants were instructed to lie on their side with the weaker limb facing upwards. Both hips were flexed at 45 degrees, the knees were flexed at 90 degrees, and neither the feet nor the back were in contact with the wall. While keeping both heels and the first metatarsal head together, participants were instructed to separate their knees and rotate the weaker limb upward. They were advised not to tilt the limb backwards and to maintain a neutral pelvic position 3,5 sets for 10 repetations twice a week for 12 weeks
Study NCT06749652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: firm silicone stent insertion
Description: Insertion of firm silicon ureteral stent (Percuflex Plus)
Study NCT06749652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft silicone ureteral stent insertion
Description: Soft silicone ureteral stent insertion
Study NCT06751199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Description: Portal vein infusion human umbilical cord mesenchymal stem cells
Study NCT06751199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic islet
Description: Portal vein infusion of allogeneic islet
Study NCT06751199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allogeneic islet
Description: Portal vein infusion of allogeneic islet
Study NCT06748664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant ODT 75mg , EOD treatment for 4/12* weeks
Description: All Participants will receive either Rimegepant 75 mg every other day for 4 weeks, followed by a 4-week observational phase.
Study NCT06748664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, EOD treatment for 4/12* weeks
Description: All Participants will receive placebo 75 mg every other day for 4 weeks, followed by a 4-week observational phase.
Study NCT05729087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended intervention group
Description: Face-to-face workshops will be delivered in the neighborhood elderly center every week. Each workshop will consist of two sections (a) a 60-minute PA session, including a Health talk (20 minutes), and a physical exercise training (40 minutes); and (b) a 60-minute healthy diet promotion, including group discussion and sharing (30 minutes), and knowledge of diet and nutrition (30 minutes).~In addition, a 15-minute online psychological session will be implemented following the PA and diet session.
Study NCT05648812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain contrast enhanced ultrasound, brain ultrasound elastography
Description: To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
Study NCT05648812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Brain contrast enhanced ultrasound, brain ultrasound elastography
Description: To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
Study NCT05648812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride
Description: To evaluate the differences in brain perfusion studied by CEUS, comparing different patient groups and babies with no suspected brain pathology
Study NCT05648812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfur Hexafluoride
Description: To evaluate the differences in brain perfusion studied by CEUS, comparing different patient groups and babies with no suspected brain pathology
Study NCT05913687 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AIDP
Description: Machine learning algorithm of imaging data
Study NCT05682664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Luchtbrug Junior (online monitoring)
Description: Online monitoring via Luchtbrug Junior will replace 50% of the outpatient visits. Children in the intervention group will be monitored online monthly by a digital version of TRACK.
Study NCT05682664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Routine outpatient clinical visits every 3 months.
Study NCT05626062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toilet alarm
Description: A Malem toilet alarm (wristworn, discretely in underwear, or bed mat) will be used to promote prompred voiding in a toilet
Study NCT05745012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic mucosal resection
Description: The procedure consists of performing endoscopic mucosal resection of the 3/4 of the circumference of the esogastric junction using the Duette system (Cook Endoscopy, USA). The procedure will be performed under general anesthesia in an intubated patient, and realized in ambulatory setting.
Study NCT05745012 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: The procedure consists of performing endoscopic exploration, no mucosal resection
Study NCT05875701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Description: 1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
Study NCT05875701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS antigen/Matrix-M Adjuvant
Description: 1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS antigen+ 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
Study NCT04842734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour